AR089004A1 - Composiciones farmaceuticas inyectables, metodo, uso - Google Patents
Composiciones farmaceuticas inyectables, metodo, usoInfo
- Publication number
- AR089004A1 AR089004A1 ARP120104457A ARP120104457A AR089004A1 AR 089004 A1 AR089004 A1 AR 089004A1 AR P120104457 A ARP120104457 A AR P120104457A AR P120104457 A ARP120104457 A AR P120104457A AR 089004 A1 AR089004 A1 AR 089004A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyclodextrin
- injectable pharmaceutical
- pharmaceutical composition
- pharmaceutical compositions
- composition according
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 4
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 230000000845 anti-microbial effect Effects 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 abstract 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 abstract 1
- DCQLZTSRKLWEAB-UHFFFAOYSA-N ac1ndudu Chemical group O1C(C(C2OCC(C)O)OCC(C)O)C(COCC(C)O)OC2OC(C(C2OCC(C)O)OCC(C)O)C(COCC(C)O)OC2OC(C(C2OCC(C)O)OCC(C)O)C(COCC(C)O)OC2OC(C(C2OCC(C)O)OCC(C)O)C(COCC(C)O)OC2OC(C(OCC(C)O)C2OCC(C)O)C(COCC(O)C)OC2OC(C(C2OCC(C)O)OCC(C)O)C(COCC(C)O)OC2OC2C(OCC(C)O)C(OCC(C)O)C1OC2COCC(C)O DCQLZTSRKLWEAB-UHFFFAOYSA-N 0.000 abstract 1
- 229960003305 alfaxalone Drugs 0.000 abstract 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 abstract 1
- 229960003184 carprofen Drugs 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 229960001929 meloxicam Drugs 0.000 abstract 1
- 239000006174 pH buffer Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 229960004134 propofol Drugs 0.000 abstract 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nanotechnology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica inyectable caracterizada porque la misma cumple con la Prueba de eficacia de la protección antimicrobiana de la Farmacopea Europea 2011, satisfaciendo por lo menos los criterios de tipo B para composiciones parenterales, y las Directrices para pruebas de efectividad antimicrobiana de la Farmacopea de los EE.UU. 2011 para los productos de la Categoría 1 (inyectables), que comprende: agua, uno o más complejos solubles en agua, cada uno de los cuales comprenden una ciclodextrina o un derivado de ciclodextrina y una droga hidrofóbica, por lo menos un conservante, por lo menos un co-solvente y opcionalmente un amortiguador de pH efectivo para proveer un pH en la composición dentro de un rango entre aproximadamente 4,0 y aproximadamente 9,0. Reivindicación 2: La composición farmacéutica inyectable de acuerdo con la reivindicación 1 caracterizada porque la droga hidrofóbica se selecciona entre el grupo que comprende: alfaxalona, propofol, meloxicam y carprofeno. Reivindicación 4: La composición farmacéutica inyectable de acuerdo con cualquiera de las reivindicaciones 1 a 3 caracterizada porque la ciclodextrina o el derivado de ciclodextrina es 2-hidroxipropil-b-ciclodextrina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011904970A AU2011904970A0 (en) | 2011-11-29 | Pharmaceutical compositions | |
AU2012904962A AU2012904962A0 (en) | 2012-11-09 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089004A1 true AR089004A1 (es) | 2014-07-23 |
Family
ID=48534526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120104457A AR089004A1 (es) | 2011-11-29 | 2012-11-28 | Composiciones farmaceuticas inyectables, metodo, uso |
Country Status (19)
Country | Link |
---|---|
US (4) | US9492552B2 (es) |
EP (2) | EP3446692A1 (es) |
JP (2) | JP5819005B2 (es) |
KR (1) | KR101922752B1 (es) |
CN (2) | CN103998046B (es) |
AR (1) | AR089004A1 (es) |
AU (1) | AU2012268889B2 (es) |
BR (1) | BR112014012985B1 (es) |
CA (1) | CA2852716C (es) |
DK (1) | DK2785352T3 (es) |
ES (1) | ES2784629T3 (es) |
HK (1) | HK1198325A1 (es) |
HR (1) | HRP20200567T1 (es) |
IL (1) | IL232860B (es) |
IN (1) | IN2014KN01341A (es) |
SG (2) | SG11201401597TA (es) |
TW (1) | TWI552770B (es) |
WO (1) | WO2013078500A1 (es) |
ZA (1) | ZA201402895B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
CN112472814A (zh) | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
RU2652783C2 (ru) | 2012-12-21 | 2018-05-03 | Санофи | Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона |
JP6180241B2 (ja) * | 2013-08-29 | 2017-08-16 | 学校法人同志社 | シクロデキストリン誘導体及び医薬組成物 |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
MX2017011103A (es) * | 2015-04-01 | 2018-05-07 | Int Dioxcide Inc | Composición estabilizada para el control de olor y la deshidratación potenciada combinados. |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
KR101718733B1 (ko) * | 2015-08-21 | 2017-03-22 | 국제약품 주식회사 | 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제 |
NL2015865B1 (en) * | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
CN110215430A (zh) * | 2018-03-02 | 2019-09-10 | 刘力 | 新型可注射的硝酸甘油药物组合物 |
KR102141826B1 (ko) * | 2018-10-05 | 2020-08-07 | 건국대학교 산학협력단 | 양이온성 베타 시클로덱스트린 올리고머를 이용한 외부 pH 자극 반응형 자가치유성 하이드로젤 |
WO2020093256A1 (zh) * | 2018-11-07 | 2020-05-14 | 比卡生物科技(广州)有限公司 | 一种澄清丙泊酚注射液及其制备方法 |
MX2021009777A (es) | 2019-02-15 | 2021-12-15 | Saol Int Development Ltd | Formulaciones inyectables de fenol y metodos de su uso. |
EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
EP3766475A1 (en) | 2019-07-15 | 2021-01-20 | OP-Hygiene IP GmbH | Wipes |
FR3117337B1 (fr) * | 2020-12-10 | 2023-04-28 | Centre Hospitalier Univ De Lille | Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable |
KR20230122271A (ko) | 2022-02-14 | 2023-08-22 | 주식회사 에이아이인사이트 | 파라벤계 보존제의 안정성 증진용 조성물 및 이를 포함하는 보존제 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4728509A (en) | 1985-08-19 | 1988-03-01 | Takeda Chemical Industries, Ltd. | Aqueous liquid preparation |
TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
JPH06293638A (ja) | 1993-04-06 | 1994-10-21 | Lion Corp | 安定なビタミンa類点眼剤 |
ZA962214B (en) * | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
JP3934705B2 (ja) | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
TW434023B (en) | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
CA2342797A1 (en) | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
AUPQ633900A0 (en) | 2000-03-20 | 2000-04-15 | Jurox Pty Ltd | Anaesthetic composition |
IN187686B (es) * | 2000-06-21 | 2002-06-08 | Bharat Serums & Vaccines Ltd | |
US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
JP2003089632A (ja) | 2001-09-17 | 2003-03-28 | Otsuka Pharmaceut Factory Inc | 注射用水性製剤 |
US20050239746A1 (en) * | 2002-02-01 | 2005-10-27 | Penkler Lawrence J | Pharmaceutical composition |
US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
JP4275394B2 (ja) | 2002-12-05 | 2009-06-10 | 株式会社大塚製薬工場 | 注射用シロスタゾール水性製剤 |
US8183230B2 (en) | 2004-01-30 | 2012-05-22 | Pfizer Inc. | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms |
US6969706B1 (en) * | 2004-05-12 | 2005-11-29 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
JP5577021B2 (ja) | 2005-02-17 | 2014-08-20 | アボット・ラボラトリーズ | 動物における障害を治療および予防するための薬剤組成物の経粘膜投与 |
CN101360503A (zh) | 2005-11-18 | 2009-02-04 | 阿斯利康公司 | 液体制剂 |
AU2009314072C1 (en) * | 2008-11-15 | 2016-11-10 | Melinta Subsidiary Corp. | Antimicrobial compositions |
SG181997A1 (en) * | 2010-01-21 | 2012-08-30 | Goodchild Invest Pty Ltd | Anaesthetic formulation |
-
2012
- 2012-11-27 AU AU2012268889A patent/AU2012268889B2/en active Active
- 2012-11-27 US US14/361,677 patent/US9492552B2/en active Active
- 2012-11-27 CN CN201280058592.1A patent/CN103998046B/zh active Active
- 2012-11-27 SG SG11201401597TA patent/SG11201401597TA/en unknown
- 2012-11-27 DK DK12853138.1T patent/DK2785352T3/da active
- 2012-11-27 EP EP18198778.5A patent/EP3446692A1/en not_active Withdrawn
- 2012-11-27 ES ES12853138T patent/ES2784629T3/es active Active
- 2012-11-27 BR BR112014012985-1A patent/BR112014012985B1/pt active IP Right Grant
- 2012-11-27 CA CA2852716A patent/CA2852716C/en active Active
- 2012-11-27 IN IN1341KON2014 patent/IN2014KN01341A/en unknown
- 2012-11-27 EP EP12853138.1A patent/EP2785352B1/en active Active
- 2012-11-27 KR KR1020147010730A patent/KR101922752B1/ko active IP Right Grant
- 2012-11-27 CN CN201710259261.9A patent/CN107261152B/zh active Active
- 2012-11-27 SG SG10201506273PA patent/SG10201506273PA/en unknown
- 2012-11-27 WO PCT/AU2012/001452 patent/WO2013078500A1/en active Application Filing
- 2012-11-27 JP JP2014542644A patent/JP5819005B2/ja active Active
- 2012-11-28 AR ARP120104457A patent/AR089004A1/es not_active Application Discontinuation
- 2012-11-29 TW TW101144782A patent/TWI552770B/zh active
-
2014
- 2014-04-22 ZA ZA2014/02895A patent/ZA201402895B/en unknown
- 2014-05-28 IL IL23286014A patent/IL232860B/en active IP Right Grant
- 2014-11-24 HK HK14111843.0A patent/HK1198325A1/zh unknown
-
2015
- 2015-02-04 JP JP2015020091A patent/JP6095707B2/ja active Active
-
2016
- 2016-09-29 US US15/280,826 patent/US10188664B2/en active Active
-
2018
- 2018-12-18 US US16/224,433 patent/US20190125762A1/en active Pending
-
2020
- 2020-04-07 HR HRP20200567TT patent/HRP20200567T1/hr unknown
-
2023
- 2023-05-26 US US18/324,305 patent/US20230293550A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089004A1 (es) | Composiciones farmaceuticas inyectables, metodo, uso | |
UY36186A (es) | Ácidos grasos novedosos y su uso en la conjugación con biomoléculas | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
CR20160099A (es) | Formulación de inhibidores de la syk | |
UY32874A (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
BR112016012146A2 (pt) | Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
CU20140068A7 (es) | Triazolopiridinas sustituidas | |
BR112015011244A2 (pt) | Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica | |
CO7180201A2 (es) | Inhibidores de neprilisina | |
CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
GT201300254A (es) | Triazolopiridinas | |
TR201908003T4 (tr) | TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları. | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
CR20170425A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
CU20120171A7 (es) | Triazolopiridinas sustituidas | |
BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
CO6741218A2 (es) | Composición pesticida y procesos relacionados con el mismo | |
CU20140037A7 (es) | Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
BR112016029842A2 (pt) | conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |